An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
|Videos|August 22, 2022
Study shows potential of ctDNA as biomarker for immunotherapy response in GU cancers
Author(s)Urology Times staff
Advertisement
Albert Jang, MD, a 3rd-year internal resident physician at Tulane University, discusses the study, “Prospective Evaluation Of Circulating Tumor Dna (ctDNA) in Detecting Early Progression on Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Cancers,” which he shared at the 2022 AUA Annual Meeting.
Advertisement
Related to this article
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
Advertisement
Advertisement